AI Engines For more Details: Perplexity Kagi Labs You
Tapeworm Infections (Cestodes): Niclosamide is highly effective against tapeworm infections, including those caused by Taenia species (such as Taenia solium, Taenia saginata, and Taenia asiatica) and other cestodes. It works by disrupting the parasite's energy metabolism, leading to paralysis and detachment from the intestinal wall, ultimately resulting in the expulsion of the worm from the body through bowel movements.
Intestinal Parasitic Infections: In addition to tapeworms, niclosamide may also have activity against other intestinal parasites, such as certain species of flukes (trematodes) and roundworms (nematodes). While not commonly used for these infections, niclosamide may be considered in specific cases where other anthelmintic drugs are ineffective or unavailable.
Cysticercosis: Niclosamide may be used as part of the treatment regimen for cysticercosis, a parasitic infection caused by the larvae of Taenia solium (pork tapeworm). Cysticercosis can affect various organs, including the brain, muscles, and eyes. Niclosamide helps eliminate the tapeworm infection and may prevent further dissemination of the larvae.
Parasitic Zoonoses: Zoonotic infections, where parasites are transmitted from animals to humans, can sometimes be treated with niclosamide. For example, tapeworm infections acquired from consuming undercooked or raw meat containing larval cysts can be effectively treated with niclosamide therapy.
Veterinary Use: Niclosamide is also used in veterinary medicine for deworming various animals, including dogs, cats, livestock, and poultry. It helps control tapeworm infections in pets and livestock, improving their health and preventing transmission to humans.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
Acne | 0.5 | -0.5 | |
ADHD | 7.5 | 1 | 6.5 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
Allergic Rhinitis (Hay Fever) | 3 | 2.5 | 0.2 |
Allergies | 7.5 | 4.5 | 0.67 |
Allergy to milk products | 2.5 | 1.5 | 0.67 |
Alopecia (Hair Loss) | 2.5 | 2.5 | |
Alzheimer's disease | 6.3 | 9.6 | -0.52 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 5.9 | 2.5 | 1.36 |
Ankylosing spondylitis | 6.4 | 3 | 1.13 |
Anorexia Nervosa | 0.5 | 3.5 | -6 |
Antiphospholipid syndrome (APS) | 3.5 | 0.3 | 10.67 |
Asthma | 2 | 2.5 | -0.25 |
Atherosclerosis | 2 | 3.5 | -0.75 |
Atrial fibrillation | 5.5 | 3.3 | 0.67 |
Autism | 16.5 | 15.2 | 0.09 |
Barrett esophagus cancer | 1 | 0.5 | 1 |
benign prostatic hyperplasia | 0.5 | 0.5 | |
Bipolar Disorder | 2.3 | 2.5 | -0.09 |
Brain Trauma | 1 | 1 | 0 |
Carcinoma | 5.8 | 4 | 0.45 |
Celiac Disease | 4 | 6.3 | -0.57 |
Cerebral Palsy | 2.5 | 2 | 0.25 |
Chronic Fatigue Syndrome | 9 | 10 | -0.11 |
Chronic Kidney Disease | 4 | 3 | 0.33 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 3.5 | 1.5 | 1.33 |
Chronic Urticaria (Hives) | 2.9 | 3 | -0.03 |
Coagulation / Micro clot triggering bacteria | 2.4 | 2 | 0.2 |
Colorectal Cancer | 7.9 | 1.5 | 4.27 |
Constipation | 2.5 | 1 | 1.5 |
Coronary artery disease | 2.5 | 1.5 | 0.67 |
COVID-19 | 18.9 | 22.9 | -0.21 |
Crohn's Disease | 13.3 | 9.4 | 0.41 |
cystic fibrosis | 1.4 | 1.5 | -0.07 |
deep vein thrombosis | 1.4 | 1.5 | -0.07 |
Depression | 16.4 | 14 | 0.17 |
Dermatomyositis | 0.5 | 0.5 | 0 |
Eczema | 2 | 3.5 | -0.75 |
Endometriosis | 4.9 | 2 | 1.45 |
Eosinophilic Esophagitis | 0.5 | 0.5 | 0 |
Epilepsy | 5 | 4.5 | 0.11 |
Fibromyalgia | 4.5 | 4.5 | 0 |
Functional constipation / chronic idiopathic constipation | 9.4 | 6.5 | 0.45 |
gallstone disease (gsd) | 3.5 | 1.5 | 1.33 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 3 | 1.5 | 1 |
Generalized anxiety disorder | 3.4 | 3 | 0.13 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 2 | 2 | 0 |
Halitosis | 1.5 | 0.5 | 2 |
Hashimoto's thyroiditis | 4 | 1.3 | 2.08 |
Hidradenitis Suppurativa | 1.3 | 0.5 | 1.6 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 5.4 | 1.5 | 2.6 |
hypercholesterolemia (High Cholesterol) | 1 | 1 | 0 |
hyperglycemia | 0.5 | 3.5 | -6 |
Hyperlipidemia (High Blood Fats) | 1.5 | 0.5 | 2 |
hypersomnia | 0.8 | -0.8 | |
hypertension (High Blood Pressure | 4 | 7.8 | -0.95 |
Hypothyroidism | 2 | -2 | |
Hypoxia | 1.5 | 1.5 | |
IgA nephropathy (IgAN) | 6.9 | -6.9 | |
Inflammatory Bowel Disease | 7.9 | 14 | -0.77 |
Insomnia | 1.5 | 1.5 | 0 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 2 | 0.5 | 3 |
Irritable Bowel Syndrome | 7.4 | 7 | 0.06 |
Liver Cirrhosis | 7.8 | 5.3 | 0.47 |
Long COVID | 13.9 | 13.7 | 0.01 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 1.5 | 2.5 | -0.67 |
ME/CFS with IBS | 2 | 4 | -1 |
ME/CFS without IBS | 3.5 | 3.5 | 0 |
Menopause | 3 | 3 | |
Metabolic Syndrome | 13.3 | 14.2 | -0.07 |
Mood Disorders | 21.3 | 14.5 | 0.47 |
multiple chemical sensitivity [MCS] | 2.5 | 0.5 | 4 |
Multiple Sclerosis | 9.8 | 8.9 | 0.1 |
Multiple system atrophy (MSA) | 3.5 | 1.5 | 1.33 |
Neuropathy (all types) | 1.5 | 0.5 | 2 |
neuropsychiatric disorders (PANDAS, PANS) | 1.5 | 1.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 8.5 | -1.13 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 13.8 | 8.5 | 0.62 |
obsessive-compulsive disorder | 10.9 | 7.5 | 0.45 |
Osteoarthritis | 4 | 0.5 | 7 |
Osteoporosis | 3 | 2 | 0.5 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 5.8 | 6.9 | -0.19 |
Polycystic ovary syndrome | 4 | 3.5 | 0.14 |
Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
Premenstrual dysphoric disorder | 1.5 | 0.5 | 2 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 7.5 | 5 | 0.5 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 11.3 | 6 | 0.88 |
Rosacea | 2 | 1 | 1 |
Schizophrenia | 11.3 | 3 | 2.77 |
scoliosis | 0.5 | 1.8 | -2.6 |
Sjögren syndrome | 5 | 5 | 0 |
Sleep Apnea | 2.5 | 2.5 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 1 | 1 |
Stress / posttraumatic stress disorder | 5 | 4.5 | 0.11 |
Systemic Lupus Erythematosus | 7.3 | 3 | 1.43 |
Tic Disorder | 2 | 2.5 | -0.25 |
Tourette syndrome | 0.5 | 0.5 | 0 |
Type 1 Diabetes | 6.3 | 4 | 0.57 |
Type 2 Diabetes | 13.8 | 12.3 | 0.12 |
Ulcerative colitis | 4.9 | 9.3 | -0.9 |
Unhealthy Ageing | 10.3 | 3.5 | 1.94 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.